New antibody cocktail aims to block HIV without daily pills

NCT ID NCT07390955

Recruiting now Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This early-stage trial is testing whether lab-made antibodies that target HIV are safe and how long they stay in the body. About 83 healthy adults without HIV will receive the antibodies by vein or under the skin, alone or in combination. The goal is to find the right dose and check for side effects, not to treat HIV yet.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lab-made antibodies (ePGT121v1-LS, PGDM1400LS, VRC07-523LS)
What this could lead to: If successful, this could point toward a new way to control HIV without daily pills, using periodic antibody infusions or shots.
What could go wrong: This is a very early Phase 1 safety study with only 83 healthy volunteers, not people with HIV. It is too soon to know if the antibodies will work against the virus in real-world conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV

Contacts and locations

Locations

Alabama CRS (Site ID: 31788)
RECRUITING

Birmingham, Alabama, 35222, United States
Bridge HIV CRS (Site ID: 30305)
RECRUITING

San Francisco, California, 94102, United States
Brigham and Women's Hospital Vaccine CRS (BWH VCRS) (Site ID: 30007)
NOT_YET_RECRUITING

Boston, Massachusetts, 02115, United States
Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales CRS (CITBM) - Unidad de Ensayos Clínicos (UNIDEC) (Site ID: 31970)
NOT_YET_RECRUITING

Bellavista, Provincia Constitucional del Callao, 07006, Peru
Houston Advancing Research Team CRS (Site ID: 31473)
NOT_YET_RECRUITING

Houston, Texas, 77030, United States
Penn Prevention CRS (Site ID: 30310)
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Seke South CRS (Site ID: 30294)
NOT_YET_RECRUITING

Harare, Zimbabwe
Spilhaus CRS (Site ID: 30314)
NOT_YET_RECRUITING

Harare, Zimbabwe
The Ponce de Leon Center CRS (Site ID: 5802)
NOT_YET_RECRUITING

Atlanta, Georgia, 30308, United States
Vanderbilt Vaccine (VV) CRS (Site ID: 30352)
RECRUITING

Nashville, Tennessee, 37232, United States
Via Libre CRS (Site ID: 31909)
NOT_YET_RECRUITING

Lima Cercado, Lima region, 15001, Peru

More trials for these conditions

Other studies related to the condition(s) this trial covers.